Sirolimus for Genetic Predisposition to Alzheimer's Disease

This trial aims to determine if sirolimus (rapamycin), a medication approved for other uses, can improve blood flow in the brains of women with the ApoE4 gene, which increases the risk for Alzheimer's disease. Participants will take either sirolimus or a placebo (a lookalike pill without active ingredients) for about four weeks. The trial is ideal for women aged 45 to 65 who are post-menopausal and do not have Alzheimer's, diabetes, or certain other health conditions. The study involves three visits over 12 weeks, including questionnaires, blood tests, and MRI scans to assess brain activity. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking research.

In earlier studies, sirolimus (also known as rapamycin) has shown potential in treating Alzheimer's disease. Research suggests that sirolimus might help protect the brain and improve memory in mice with Alzheimer's. The FDA has already approved this drug for use in organ transplant patients, indicating that some safety information is already known.

Unlike the standard treatments for Alzheimer's, which mainly focus on managing symptoms through medications like donepezil or memantine, sirolimus (also known as rapamycin) offers a different approach. Sirolimus is unique because it targets the biological processes related to aging, specifically by inhibiting a protein called mTOR. This mechanism might help slow down or prevent the progression of Alzheimer's, particularly for those with a genetic predisposition. Researchers are excited about sirolimus because it could potentially modify the underlying disease process rather than just alleviating symptoms, offering hope for a more effective intervention.

Research suggests that sirolimus, also known as rapamycin, might help with Alzheimer's disease. In animal studies where subjects developed Alzheimer's, sirolimus improved learning and memory. Researchers believe sirolimus may help by boosting blood flow to the brain, which is crucial for maintaining brain health. Additionally, sirolimus has shown potential in increasing lifespan in other studies, making it a promising candidate for further research in Alzheimer's prevention. In this trial, participants will receive either sirolimus or a placebo to assess its effectiveness in individuals with a genetic risk for Alzheimer's. Although research in humans is still ongoing, these early results provide a reason to explore its potential benefits.⁶⁷⁸⁹¹⁰